SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of: August 2021
Commission File Number: 001-39152
FSD PHARMA INC.
(Translation of registrant's name into English)
199 Bay St., Suite 4000
Toronto, Ontario M5L 1A9, Canada
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☐ Form 40-F ☒
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
INCORPORATION BY REFERENCE
Each of (a) the Registrant's Material Change Report dated August 31, 2021 (regarding the termination of the Phase 2 clinical trial of FSD-201), included as Exhibit 99.1 of this Form 6-K (Commission File No. 001-39152), furnished to the Commission on the date hereof, and (b) the Registrant's Material Change Report dated August 31, 2021 (regarding a definitive agreement to acquire Lucid Psycheceuticals Inc.), included as Exhibit 99.2 of this Form 6-K, furnished to the Commission on the date hereof, is incorporated by reference into the Registrant's Registration Statements on Form F-10 (Commission File Nos. 333-236780 and 333-254995).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
FSD Pharma Inc.
|Date: August 31, 2021||By:||/s/ Nathan Coyle|
|Nathan Coyle, Chief Financial Officer|